Matching articles for "page 25"
Issue 1335 · April 5, 2010
Liraglutide (Victoza) for Type 2 Diabetes

Liraglutide ( Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can…

Med Lett Drugs Ther. 2010 Apr 5; 52(1335):25-7
Liraglutide ( Victoza – Novo Nordisk), a glucagon-like peptide-1 (GLP-1) receptor agonist given by subcutaneous injection, has been approved by the FDA for treatment of patients with type 2 diabetes. It can be used alone or in addition to oral antidiabetic drugs such as metformin ( Glucophage , and others) or glimepiride ( Amaryl , and others). Liraglutide is not recommended for first-line therapy and is not approved for use with insulin.
Issue 1310 · April 20, 2009 Free
Correction: Vancomycin Dosing and Monitoring

(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the…

Med Lett Drugs Ther. 2009 Apr 20; 51(1310):32
(Med Lett Drugs Ther 2009; 51:25) In the paragraph on dosing, the second-to-last sentence should have said that the new recommendations suggest considering use of an alternative antibiotic when the MIC for the infecting organism is ≥2 mg/L, not >2 mg/L .
Issue 1309 · April 6, 2009
Vancomycin Dosing and Monitoring

Consensus recommendations for dosing and therapeutic monitoring of intravenous (IV) vancomycin ( Vancocin , and others) were recently published. IV vancomycin has been used for decades as an alternative to…

Med Lett Drugs Ther. 2009 Apr 6; 51(1309):25
Consensus recommendations for dosing and therapeutic monitoring of intravenous (IV) vancomycin ( Vancocin , and others) were recently published. IV vancomycin has been used for decades as an alternative to penicillins for treatment of serious infections due to gram-positive cocci. In recent years, the widest use of the drug has been for treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections.
Issue 1283 · April 7, 2008
Simcor: A Niacin/Simvastatin Combination

The FDA has approved the marketing of a second fixed-dose combination of extended-release niacin ( Niaspan ) with a generic statin. Niaspan/simvastatin ( Simcor - Abbott) is approved for use in patients with…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):25-6
The FDA has approved the marketing of a second fixed-dose combination of extended-release niacin ( Niaspan ) with a generic statin. Niaspan/simvastatin ( Simcor - Abbott) is approved for use in patients with hypercholesterolemia or mixed dyslipidemia (high LDL-cholesterol, low HDL-cholesterol and high serum triglycerides). Niaspan /lovastatin ( Advicor ) was marketed previously for the same indications.
Issue 1283 · April 7, 2008 Free
In Brief: Meningococcal Prophylaxis

The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR,…

Med Lett Drugs Ther. 2008 Apr 7; 50(1283):25
The CDC recently reported that fluoroquinoloneresistant strains of Neisseria meningitidis have been detected for the first time in the US in an area around the border of North Dakota and Minnesota (CDC. MMWR, Feb 22, 2008). These isolates were all serogroup B, for which meningococcal vaccines ( Med Lett Drugs Ther 2005; 47:29 ) do not offer protection. Since many laboratories do not test N. meningitidis for antimicrobial susceptibility, it is possible that such resistance is more widespread. A single oral dose of ciprofloxacin ( Cipro , and others) 500 mg has been used for prophylaxis after close contact with infected patients. Oral rifampin ( Rifadin , and others) 600 mg (10 mg/kg for children) q12h for 2 days, a single IM injection of ceftriaxone ( Rocephin , and others) 250 mg (125 mg for children), or a single oral dose of azithromycin ( Zithromax , and others) 500 mg (10 mg/kg for children) are reasonable alternatives. Download U.S. English
Issue 1257 · March 26, 2007
Once-Daily Mesalamine (Lialda) for Ulcerative Colitis

A once-daily oral formulation of mesalamine ( Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.

Med Lett Drugs Ther. 2007 Mar 26; 49(1257):25-6
A once-daily oral formulation of mesalamine ( Lialda - Shire) was recently approved by the FDA for induction of remission in patients with mild to moderate ulcerative colitis.